Arbutus生物製藥 ABUS 深 滬
等待開盤 03-26 09:30:00 美东时间
4.53
+0.220
+5.10%
華盛通- 最 高4.64
- 今 開4.40
- 成交量 254.79万股
- 最 低 4.385
- 昨 收 4.31
- 總市值 8.70亿
- 52周最高 5.10
- 市盈率 靜 --
- 換手率 1.33%
- 52周最低 2.705
- 委 比 -96.30%
- 總股本 1.92亿
- 歷史最高 31.48
- 量 比 0.80
- 振 幅 5.92%
- 歷史最低 0.821
- 每 手 1
- 風險率 0.58%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Arbutus Biopharma Q4 EPS $(0.01) Beats $(0.03) Estimate, Sales $1.051M Miss $1.233M Estimate
Arbutus Biopharma (NASDAQ:ABUS) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.03) by 66.67 percent. This is a 85.71 percent increase over losses of $(0.07) per share from
03-23 19:44
Arbutus Biopharma advances imdusiran and AB-101 for chronic hepatitis B treatment
Arbutus Biopharma advances imdusiran and AB-101 for chronic hepatitis B treatment Arbutus said it is developing imdusiran (AB-729) and AB-101 for chronic hepatitis B, positioning the company to compete in combination regimens aimed at improving treatment outcomes. Management stated that more than 20
03-23 19:32
Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
Arbutus Biopharma reported strong financial results for 2025, with $91.5M in cash and marketable securities. The company achieved a significant milestone with a $950M settlement from Moderna for LNP technology infringement. Additionally, two more patients in the Phase 2a trials of imdusiran achieved functional cure for chronic hepatitis B. The company also received a milestone payment for its HCC treatment candidate. Financial performance showed ...
03-23 11:30
美股机会日报 | 传伊朗特工秘密接触中情局！并讨论停火价码；美财长贝森特称15%关税本周内将实施
传伊朗特工秘密接触中情局！纳指期货盘前拉升涨0.6%；美财长贝森特称15%关税本周内将实施；比特币重回7.1万美元上方！加密货币概念股普涨，Strategy涨近7%>>
03-04 21:16
Market-Moving News for March 4th
MRNA: 11% | Moderna shares are trading higher after the company announced that it has entered into a settlement agreement with Arbutus Biopharma and Genevant Sciences. CANF: 54% | Can-Fite
03-04 20:20
Roivant Subsidiary Reaches Major Global Patent Settlement
Roivant Sciences ( ($ROIV) ) has provided an update. On March 3, 2026, Roivant’...
03-04 06:14
Moderna Stock Jumps 10% After Hours: Here's Why
Moderna shares are rising in Tuesday's after-hours session after the company announced it reached a settlement agreement.
03-04 05:55
Roivant Sciences' Subsidiary, Arbutus Biopharma Sign $2.25B Settlement With Moderna To Resolve All U.S., Global Enforcement Actions; Moderna To Pay $950M Upfront Payment To Genevant, Arbutus
Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle (LNP) patent portfolio and a subsidiary of Roivant Sciences Ltd. (NASDAQ:ROIV), and Arbutus Biopharma
03-04 05:18
Roivant Announces Genevant Sciences’ and Arbutus Biopharma’s $2.25 Billion Global Settlement With Moderna
Moderna, Inc. has reached a $2.25 billion global settlement with Genevant Sciences and Arbutus Biopharma to resolve patent infringement disputes over their lipid nanoparticle (LNP) delivery technology used in its COVID-19 vaccines. Moderna will pay $950 million upfront and an additional $1.3 billion contingent on a favorable appellate ruling. The settlement includes a global non-exclusive license for Moderna to use the LNP technology for infectio...
03-03 21:15
Moderna dealt blows in ongoing patent dispute with Arbutus
A federal judge in Delaware has thrown out two key defenses Moderna (MRNA) had been claiming in its ongoing patent litigation with Arbutus Biopharma (ABUS) regarding its mRNA COVID-19 vaccine. Judge J...
02-18 22:42
